BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Total Liabilities
Everything the company owes to creditors and other parties.
BioAge Labs, Inc.NASDAQ: BIOA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 39.6% from a year ago
Total liabilities stood at $18.53M at the end of Q1 FY2026, down 39.6% from a year earlier and down 18.9% from the prior quarter. Over 3 fiscal years it compounded at -45.5% a year.
Context
- Total liabilities amounted to 4.7% of total assets at the end of Q1 FY2026, down 4.3 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -39.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.84M USD
- Year-over-year change
- -34.9%
- 3-year CAGR
- -45.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.84M | -34.9% |
| FY2024 | 2024-12-31 | 35.11M | -82.4% |
| FY2023 | 2023-12-31 | 199.32M | +41.4% |
| FY2022 | 2022-12-31 | 140.99M | — |
Total Liabilities vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -39.6% is the 8th highest of 9, against a peer median of -4.6%.
- Total liabilities amounts to 4.7% of total assets for BIOA, versus a peer median of 34.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$421.14M CAD | -2.2% | -29.6% | 37.6% | |
| Dec 2025 | $246.38M USD | — | — | 106.1% | |
| Mar 2026 | $144.93M USD | -28.0% | +1.2% | 97.0% | |
| Mar 2026 | $117.08M USD | -4.5% | -7.3% | 29.6% | |
| Mar 2026 | $98.93M USD | -21.8% | +9.0% | 89.5% | |
| Mar 2026 | CA$89.49M CAD | -63.1% | -39.5% | 14.8% | |
| Mar 2026 | $44.84M USD | +2.9% | +62.1% | 30.3% | |
| Mar 2026 | $33.73M USD | -4.7% | -12.7% | 34.2% | |
| Mar 2026 | $33.37M USD | +15.5% | +15.0% | 12.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M USD | -39.6% | -45.5% | 4.7% |
| Peer median (excluding BIOA) | — | -4.6% | -3.0% | 34.2% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.